Antimicrobial Coating for Biofilm Inhibition

描述(申请人提供)：念珠菌是第三大致病原因 导管相关的医院血流感染。留置装置有 已被证明支持念珠菌的定植和生物膜形成。 静脉导管是最常见的留置装置，也是 念珠菌血症最常见的原因。一旦假丝酵母菌在体内形成生物膜，就可以去除 为了消除感染，几乎总是需要对支持生物膜生长的底物进行消毒。不幸的是，在许多情况下，删除 是不可能的，因为病人的情况恶化，解剖位置或 潜在的疾病。 该项目的目标是将一种抗真菌药物加入到独特的， 获得专利的配方，为医疗器械创造一种耐腐蚀涂层 对白色念珠菌。一种涂层和抗真菌递送系统，可以延长 时间和/或提高交付速度，并实现更高的集中度 抗真菌药物对白色念珠菌敏感部位会有巨大的 与全身和无效的局部途径相比，治疗上的优势 送货。为了论证这一方法的可行性，具体目的是 是为了优化涂层配方以用作短期抗真菌药物 医疗器械用涂层的抗真菌活性评价 并在兔体内进行肌内植入研究。 建议的商业应用：到目前为止，白色念珠菌是最常见的分离的人类霉菌制剂。大量使用留置装置的免疫抑制患者，加上与治疗白色念珠菌相关感染相关的广泛社会和经济成本，为寻求替代疗法提供了理由。

Description(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that is supporting the biofilm growth is almost always required to eliminate the infection. Unfortunately, in many instances removal is impossible due to deteriorated patient condition, anatomical location, or underlying disease. The goal of this project is to incorporate an antifungal agent into unique, patented formulations to create a coating for medical devices that is resistant to C. albicans. A coating and antifungal delivery system that could extend the time and/or increase the rate of delivery and achieve a higher concentration of antifungal agents to a C. albicans-susceptible site would have enormous therapeutic advantages over systemic and inefficacious topical routes of delivery. To demonstrate the feasibility of this approach, the specific aims are to optimize the coating formulation for use as short-term antifungal coatings for medical devices, evaluate the coatings for antifungal activity in vitro, and to perform an intramuscular implantation study in rabbits. PROPOSED COMMERCIAL APPLICATION: Candida albicans is by far the most frequently isolated human mycotic agent. The large number of immunosuppressed patients with indwelling devices combined with the extensive social and economic costs associated with treating C. albicans-related infections serve as justification for the pursuit of alternative therapies.